Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tolvaptan

Generic Name: Tolvaptan

Brand Names: Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₅ClN_₂O_₃

CAS Number: 150683-30-0

Unique Ingredient Identifier: 1E2497LPNY

Overview

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

Background

Indication

Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.

Associated Conditions

Autosomal Dominant Polycystic Kidney Disease （ADPKD)
Symptomatic euvolemic Hyponatremia
Symptomatic hypervolemic Hyponatremia

Clinical Trials

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Phase 2

Recruiting

Posted: 2024/11/21

Sponsor:M.D. Anderson Cancer...

ID:NCT06698822

Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

Early Phase 1

Not yet recruiting

Posted: 2024/11/15

Sponsor:

Beijing Tiantan Hosp...

ID:NCT06689982

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Posted: 2024/11/14

Sponsor:Tongji Hospital

ID:NCT06688838

JAK Inhibitor Dose TAPering Strategy Study

Phase 4

Not yet recruiting

Posted: 2024/11/13

Sponsor:University Hospital,...

ID:NCT06687551

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Phase 3

Not yet recruiting

Posted: 2024/10/23

Sponsor:Duke University

ID:NCT06654882

FDA Approved Products

XELJANZ XR

Manufacturer:Pfizer Laboratories Div Pfizer Inc

Route:ORAL

Strength:11 mg in 1 1

Approved: 2023/05/23

NDC:0069-0501

tolvaptan

Manufacturer:Apotex Corp.

Route:ORAL

Strength:15 mg in 1 1

Approved: 2023/12/15

NDC:60505-4317

XELJANZ

Manufacturer:Pfizer Laboratories Div Pfizer Inc

Route:ORAL

Strength:5 mg in 1 1

Approved: 2023/05/23

NDC:0069-1001

Tolvaptan

Manufacturer:Ascend Laboratories, LLC

Route:ORAL

Strength:30 mg in 1 1

Approved: 2022/09/07

NDC:67877-636

Tolvaptan

Manufacturer:Ascend Laboratories, LLC

Route:ORAL

Strength:60 mg in 1 1

Approved: 2022/09/07

NDC:67877-637

Singapore Approved Products

JINARC TABLET 45MG/15MG

Manufacturer:Otsuka Pharmaceutical Co., Ltd. - Tokushima Factory (DP intermediate), Otsuka Pharmaceutical Co., Ltd. - Tokushima Itano Factory, AndersonBrecon (UK) Ltd. (Primary and Secondary Packager)

Form:TABLET

Strength:45.0mg

Online:Yes

Approved: 2022/09/23

Approval:SIN16609P

JINARC TABLET 60MG/30MG

Form:TABLET

Strength:30.000mg

Online:Yes

Approved: 2022/09/23

Approval:SIN16610P

JINARC TABLET 30MG

Manufacturer:Otsuka Pharmaceutical Co., Ltd. - Tokushima Factory (DP intermediate), Otsuka Pharmaceutical Co., Ltd. - Tokushima Itano Factory, PT Otsuka Indonesia (Primary packager and Secondary packager)

Form:TABLET

Strength:30.000mg

Online:Yes

Approved: 2022/09/23

Approval:SIN16608P

XELJANZ TABLET 5MG

Manufacturer:Pfizer Manufacturing Deutschland GmbH

Form:TABLET, FILM COATED

Strength:8.078mg

Online:Yes

Approved: 2014/11/17

Approval:SIN14664P

JINARC TABLET 90MG/30MG

Form:TABLET

Strength:90.0mg

Online:Yes

Approved: 2022/09/23

Approval:SIN16611P

Related News

CAGE Bio Initiates Phase 2b Trial of Topical JAK Inhibitor CGB-500 for Atopic Dermatitis

5 months ago

CAGE Bio has commenced a Phase 2b dose-ranging trial for CGB-500, a topical JAK inhibitor, to treat moderate to severe atopic dermatitis.

Ionic Liquids Enhance Topical Drug Delivery for Skin Diseases

5 months ago

Ionic liquids, liquid salts with unique properties, are being explored to improve the delivery of therapeutics into the skin, enhancing drug solubilization and skin permeability.

Lupin Gains FDA Approvals for HIV, Cystic Fibrosis, and Heart Failure Generics

7 months ago

Lupin receives FDA approval for generic Sacubitril/Valsartan tablets, a heart failure therapy, targeting a $6.06 billion market.

Advancements in CGB-500 for Atopic Dermatitis Treatment

a year ago

CAGE Bio Inc. is making strides in dermatological drug development with its ionic liquid formulation, CGB-500, showing promising results in clinical trials for atopic dermatitis. The company's CEO, Nitin Joshi, PhD, shared insights into the development process and the potential of this innovative treatment approach.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy